Znachenie urovnya timidilatsintetazy dlya prognoza i effekta khimioterapii pri kolorektal'nom rake


Cite item

Full Text

Abstract

В химиотерапию колоректального рака в последние годы вошел ряд новых активных препаратов, таких как оксалиплатин, томудекс, иринотекан, капецитабин и др. В настоящее время активно изучаются новые биохимические опухолевые маркеры, способствующие выбору рациональной химиотерапии. Тимидилатсинтетаза (ТС) является одним из ключевых ферментов, контролирующих репликацию ДНК Ингибиторы ТС занимают значительное место в химиотерапии колоректального рака. Работа выполнена при поддержке федеральной программы “Исследования и разработки по приоритетным направлениям развития науки и техники гражданского значения” в рамках проекта “Разработка новых методов лекарственной терапии больных злокачественными заболеваниями на основе анализа ангиогенных свойств опухоли”.

About the authors

O V Absalyamova

Российский онкологический научный центр им. Н.Н.Блохина РАМН

E V Stepanova

Российский онкологический научный центр им. Н.Н.Блохина РАМН

M R Lichinitser

Российский онкологический научный центр им. Н.Н.Блохина РАМН

References

  1. Danenberg P.V. Thymidylate synthase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977; 473: 73-92.
  2. Longley D, Harkin D.P, Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Rew 2003; 3 (5): 330-8.
  3. Diasio R.B. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Huntingt) 2001; 15 (Suppl. 2): 21-6; discussion 27.
  4. Jackman A.L, Taylor G.A, Gibson W et al. ICI D1694, a quinazonile antifolate thymidylate syntase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51: 5579-86.
  5. Cascinu S, Aschele C, Barni S et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin - modulated bolus 5-fluorouracil. Clin Cancer Res 1999; 5: 1996-9.
  6. Johnston P.G, Fisher E.R, Rockette H.E et al. The role of thymidylate synthase expression in prognosis abd outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-7.
  7. Fujiwara H, Terashima M, Irinoda T et al. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real - time RT-PCR. Jpn J Cancer Res 2002; 93 (12): 1342-50.
  8. Leichman C.G, Lenz H.J, Leichman L et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted - infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15: 3223-9.
  9. Salonga D, Danenberg K.D, Johnson M et al. Colorectal tumors responding to 5-fluororacil have low gene expression levels of dehydropyridimine dehydrohenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-7.
  10. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2002; 86 (8): 1365.
  11. Kawakami K, Salonga D, Park J.M et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001; 7: 4096-101.
  12. Johnston P.G, Drake J.C, Trepel J, Allegra C. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil - sensitive and - resistant human cancer cell lines. Cancer Res 1992 Aug.; 52: 4306-12.
  13. Johnston P.G, Lenz H.J, Leichman C.G et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
  14. Cascinu S, Graziano F, Valentini M et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node - positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 2001; 12 (2): 239-44.
  15. Tomiak A, Vincent M, Earle C.C et al. Thymidylate synthase expression in stage II and III colon cancer: a retrospective review. Am J Clin Oncol 2001; 24 (6): 597-602.
  16. Wong N.A, Brett L, Stewart M et al. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma. Br J Cancer 2001; 85 (12): 1937-43.
  17. Aschele C, Debernardis D, Tunesi G et al. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 2000; 6 (12): 4797-802.
  18. Corsi D.C, Ciaparrone M, Zannoni G et al. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer 2002; 38 (4): 527-34.
  19. Bertino J, Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? Clin Cancer Res 2003; 9: 1235-9.
  20. Allegra C.J, Parr A.L, Wold L.E et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002; 20: 1732-43.
  21. Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003; 8: 72-8.
  22. Peters G.J, Backus H.H, Freemantle S et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194-205.
  23. Edler D, Glimelius B, Hallstrom M et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil.-.based chemotherapy. J Clin Oncol 2002; 20: 1721-8.
  24. Sobrero A, Aschele C, Bertino J.R. Fluorouracil in colon cancer: a tale of two drugs: implication for biochemical modulation. J Clin Oncol 1997; 15: 368-81.
  25. Araki Y, Isomoto H, Shirouzu K. Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer. Kurume Med J 2001; 48 (2): 93-8.
  26. Farrugia D.C, Ford H.E.R, Cunningham D et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to Raltitrexed. Clin Cancer Res 2003; 9: 792-801.
  27. Peters G.J, van Triest B, Backus H.H et al. Molecular downstream events and induction of thymidylate synthase in mutant and wild - type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 2000; 36 (7): 916-24.
  28. Van Triest B, Pinedo H.M, Giaccone G, Peters G.J. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000; 11 (4): 385-91.
  29. Patterson A.V, Talbot D.C, Stratford I.J, Harris A.L. Thymidine phosphorylase moderates thymidine - dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro. Cancer Res 1998; 58: 2737-40.
  30. Brienza S, Bensmaine M.A, Soulie P et al. Oxaliplatin added to 5-fluorouracil - based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate - use program. Ann Oncol 1999; 10 (11): 1311-6.
  31. Lichinitser M, Garin A, Gorbunova V et al. Oxaliplatin (Oxa) combined with 4-hour 5-fluoro - uracil (5-FU) infusion and folinic acid (FA) every 2 weeks in patients with metastatic colorectal cancer (MCRC). Proc Am S Clin Oncol 2001; 20: 143a. Abstract 569.
  32. Bras-Goncalves R.A, Pocard M, Formento J.L et al. Synergistic efficacy of 3n - butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology 2001; 120 (4): 874-88.
  33. Schmitz J.C, Yu D, Agrawal S, Chu E. Effect of 2'-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells. Nucleic Acids Res 2001; 29 (2): 415-22.

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies